Autolus Therapeutics plc
Autolus Therapeutics plc (AUTL) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · AUTL · as of Mar 31, 2025
Ownership Breakdown
98
Institutional Holders
▼ 13 vs Q4
$260.95M
Total Inst. Value
▼ $134.40M vs Q4
266.14M
Shares Outstanding
freeFloat 90.37%
168.09M
13F Shares Held
▼ 353,102 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
AUTL largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
WELLINGTON MANAGEMENT GROUP LLP biological products, (no diagnostic substances) | 27.09M | 10.18% | 10.18% | $41.99B | May 13, 2025 | ▲ 1.75M |
BLACKSTONE INC. biological products, (no diagnostic substances) | 20.49M | 7.70% | 7.70% | $31.75B | May 15, 2025 | — held |
DEEP TRACK CAPITAL, LP biological products, (no diagnostic substances) | 17.85M | 6.71% | 6.71% | $27.67B | May 15, 2025 | ▲ 3.63M |
SYNCONA PORTFOLIO LTD biological products, (no diagnostic substances) | 16.64M | 6.25% | 6.25% | $25.79B | May 7, 2025 | — held |
ARMISTICE CAPITAL, LLC biological products, (no diagnostic substances) | 11.00M | 4.13% | 4.13% | $17.05B | May 15, 2025 | ▲ 1.80M |
FMR LLC biological products, (no diagnostic substances) | 10.16M | 3.82% | 3.82% | $15.75B | May 12, 2025 | ▼ 5.47M |
AVORO CAPITAL ADVISORS LLC biological products, (no diagnostic substances) | 9.91M | 3.72% | 3.72% | $15.36B | May 15, 2025 | — held |
TFG ASSET MANAGEMENT GP LTD biological products, (no diagnostic substances) | 8.60M | 3.23% | 3.23% | $13.33B | May 15, 2025 | ▲ 350.0K |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.62M | 1.74% | 1.74% | $7.17B | May 15, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 3.94M | 1.48% | 1.48% | $6.11B | May 2, 2025 | ▼ 183.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
19
Increased
+12.20M shares5
New Positions
first time holders16
Decreased
−9.15M shares0
Sold Out
fully exitedNet shares change (top 50)
+3.05M
+12.20M / −9.15M
Net new holders
+8
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
AUTL insider trading · insider activity
Source: SEC Form 4
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
No recent insider transactions reported.
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Autolus Therapeutics plc (AUTL) is primarily owned by institutional investors, who hold approximately 63.2% of total shares outstanding. Company insiders own approximately 9.63%, while retail and public investors account for the remaining 27.21%.
The largest institutional shareholder of Autolus Therapeutics plc is WELLINGTON MANAGEMENT GROUP LLP, holding approximately 27.09 million shares — equal to 10.18% of outstanding shares — as of March 31, 2025.
A total of 98 institutional investors currently hold AUTL stock, with a combined institutional value of approximately $260,954,922 as of the most recent 13F filing period.
Frequently asked questions
AUTL ownershipAutolus Therapeutics plc (AUTL) is primarily owned by institutional investors, who hold approximately 63.2% of shares. The largest shareholder is WELLINGTON MANAGEMENT GROUP LLP with a 10.18% stake. Company insiders hold 9.63%. Data sourced from SEC Form 13F as of March 31, 2025.